心脏磁共振组织追踪在原发性肥厚型心肌病中的真实世界临床有效性
这项历史前瞻性研究纳入33例患者,评估心脏磁共振组织追踪(CMR-TT)应变值在原发性肥厚型心肌病(HCM)中的诊断有效性与临床验证。结果显示应变参数阅片一致性良好,HCM患者与健康对照间差异显著,包含常规风险因素与所有应变值的预测模型AUC达98%,优于仅用常规风险因素(86%)。
要点
- CMR-TT应变参数在HCM患者中阅片一致性良好,与健康对照及肥厚/LGE+节段相比形变能力显著降低。
- 包含常规风险因素与所有应变值的MACE预测模型AUC为98%(95%CI .94-1),仅用常规风险因素为86%(95%CI .73-99)。
- CMR-TT应变在常规临床特征与传统CMR标志物之外提供独立且不可忽视的预后优势。
核心结论
- 在原发性HCM患者中,CMR-TT应变具有高临床有效性,较临床特征和传统CMR标志物提供独立且不可忽视的预后优势。
研究设计与样本
- 历史前瞻性研究,纳入33例患者,评估应变值的诊断有效性与临床验证。
- CMR-TT诊断有效性通过比较HCM患者与健康对照组及HCM表型表现进行研究。
- 应变值与所有表型疾病特征对长期随访的影响被评估。
关键影像表现/征象
- 肥厚节段和LGE+节段较健康节段显示更低的形变能力。
- 所有应变参数的阅片间一致性良好。
- 健康对照组与HCM患者之间观察到显著差异。
诊断标准与关键数值
- 包含MACE发生常规风险因素与所有应变值的预测模型AUC为98%(95%CI .94-1;标准误 .02;P值 .0001)。
- 仅包含常规风险因素的预测模型AUC为86%(95%CI .73-99;标准误 .07;P值 .002)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Cardiac magnetic resonance (CMR) is an uncontested diagnostic tool for identifying and assessing hypertrophic cardiomyopathy (HCM) patients. Concerning the necessity to identify valid prognosticators for predicting the individual risk of clinical evolution, this study aimed to evaluate the clinical validity of CMR tissue tracking (TT) analysis in patients affected by primitive HCM in a real-world setting.
METHODS: This historical prospective study included 33 patients. Diagnostic validity and clinical validation were assessed for strain values. CMR-TT diagnostic validity was studied comparing HCM patients with healthy control groups and phenotypic presentation of HCM. The impact of strain values and all phenotypic disease characteristics were assessed in a long-term follow-up study.
RESULTS: The inter-reading agreement was good for all strain parameters. Significant differences were observed between the control group and HCM patients. Similarly, hypertrophic and LGE + segments showed lower deformability than healthy segments. The AUC of predictive model, including conventional risk factors for MACE occurrence and all strain values, reached 98% of diagnostic concordance (95% CI .94-1; standard error: .02; p value .0001), compared to conventional risk factors only (86%; 95% CI .73-99; standard error: .07; p value .002).
CONCLUSION: In patients with primitive HCM, CMR-TT strain proves high clinical validity providing independent and non-negligible prognostic advantages over clinical features and traditional CMR markers.
引用
- Palumbo, Masedu, De Cataldo, et al. Real-world clinical validity of cardiac magnetic resonance tissue tracking in primitive hypertrophic cardiomyopathy. Radiol Med. 2021. PMID: 34894317. doi:10.1007/s11547-021-01432-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。